Search

Your search keyword '"Sarita R. Mendonca"' showing total 3 results
Start Over Author "Sarita R. Mendonca"
3 results on '"Sarita R. Mendonca"'

1. The transmembrane isoform of Plasmodium falciparum MAEBL is essential for the invasion of Anopheles salivary glands.

Author

Fabian E Saenz, Bharath Balu, Jonah Smith, Sarita R Mendonca, and John H Adams

Subjects
Medicine, Science
Abstract

Malaria transmission depends on infective stages in the mosquito salivary glands. Plasmodium sporozoites that mature in midgut oocysts must traverse the hemocoel and invade the mosquito salivary glands in a process thought to be mediated by parasite ligands. MAEBL, a homologue of the transmembrane EBP ligands essential in merozoite invasion, is expressed abundantly in midgut sporozoites. Alternative splicing generates different MAEBL isoforms and so it is unclear what form is functionally essential. To identify the MAEBL isoform required for P. falciparum (NF54) sporozoite invasion of salivary glands, we created knockout and allelic replacements each carrying CDS of a single MAEBL isoform. Only the transmembrane form of MAEBL is essential and is the first P. falciparum ligand validated as essential for invasion of Anopheles salivary glands. MAEBL is the first P. falciparum ligand experimentally determined to be essential for this important step in the life cycle where the vector becomes infectious for transmitting sporozoites to people. With an increasing emphasis on advancing vector-based transgenic methods for suppression of malaria, it is important that this type of study, using modern molecular genetic tools, is done with the agent of the human disease. Understanding what P. falciparum sporozoite ligands are critical for mosquito transmission will help validate targets for vector-based transmission-blocking strategies.

Published
2008
Full Text
View/download PDF

2. Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation

Author

Vladimir Vainstein, Lena A. Basile, Hue Kha, Sarita R. Mendonca, and Zoya Gluzman-Poltorak

Subjects
Male, medicine.medical_specialty, Cancer Research, Biology, Placebo, Gastroenterology, Sepsis, Subcutaneous injection, Random Allocation, Internal medicine, Total body irradiation, medicine, Animals, Humans, Survival rate, Molecular Biology, Radiation, Research, HSARS, Acute Radiation Syndrome, Hematology, Syndrome, medicine.disease, Interleukin-12, Macaca mulatta, Recombinant Proteins, Surgery, Hematopoiesis, Survival Rate, Radiation Injuries, Experimental, medicine.anatomical_structure, Oncology, IL-12, Toxicity, Female, Bone marrow, Whole-Body Irradiation
Abstract

Background The hematopoietic syndrome of the acute radiation syndrome (HSARS) is a life-threatening condition in humans exposed to total body irradiation (TBI); no drugs are approved for treating this condition. Recombinant human interleukin-12 (rHuIL-12) is being developed for HSARS mitigation under the FDA Animal Rule, where efficacy is proven in an appropriate animal model and safety is demonstrated in humans. Methods In this blinded study, rhesus monkeys (9 animals/sex/dose group) were randomized to receive a single subcutaneous injection of placebo (group 1) or rHuIL-12 at doses of 50, 100, 250, or 500 ng/kg (groups 2–5, respectively), without antibiotics, fluids or blood transfusions, 24–25 hours after TBI (700 cGy). Results Survival rates at Day 60 were 11%, 33%, 39%, 39%, and 50% for groups 1–5, respectively (log rank p

Published
2014

3. HemaMax™, a Recombinant Human Interleukin-12, Is a Potent Mitigator of Acute Radiation Injury in Mice and Non-Human Primates

Author

Lena A. Basile, Dolph D. Ellefson, Sarita R. Mendonca, Jamie Tom, Zoya Gluzman-Poltorak, Joseph D. Miller, Vernon Mar, Katiana S. Junes-Gill, Alice T Trinh, and Timothy K. Gallaher

Subjects
Male, Anatomy and Physiology, Myeloid, Lipopolysaccharide Receptors, lcsh:Medicine, Mice, Immune Physiology, Intestine, Small, Blood plasma, lcsh:Science, Multidisciplinary, Receptors, Interleukin-12, Total body irradiation, Interleukin-12, Recombinant Proteins, Radiation Injuries, Experimental, Dose–response relationship, Haematopoiesis, Treatment Outcome, medicine.anatomical_structure, Medicine, Female, Megakaryocytes, Research Article, Biotechnology, medicine.drug, Drugs and Devices, medicine.medical_specialty, Immunology, Biology, Interferon-gamma, Pharmacokinetics, Internal medicine, medicine, Animals, Humans, Osteoblasts, Dose-Response Relationship, Drug, lcsh:R, Radiobiology, Molecular Development, Hematopoietic Stem Cells, Macaca mulatta, Hematopoiesis, Mice, Inbred C57BL, Endocrinology, Gene Expression Regulation, Erythropoietin, Immune System, Pharmacodynamics, Leukocytes, Mononuclear, Clinical Immunology, lcsh:Q, Biomarkers, Developmental Biology
Abstract

HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medical need for effective treatments against acute radiation syndrome due to radiological terrorism or accident when administered at least 24 hours after radiation exposure. This study investigated pharmacokinetics, pharmacodynamics, and efficacy of m-HemaMax (recombinant murine IL-12), and HemaMax to increase survival after total body irradiation (TBI) in mice and rhesus monkeys, respectively, with no supportive care. In mice, m-HemaMax at an optimal 20 ng/mouse dose significantly increased percent survival and survival time when administered 24 hours after TBI between 8-9 Gy (p

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results